Retrospective Study
Copyright ©The Author(s) 2025.
World J Gastroenterol. Feb 7, 2025; 31(5): 102210
Published online Feb 7, 2025. doi: 10.3748/wjg.v31.i5.102210
Table 2 Univariable regression analysis for disease-free survival, overall survival and cancer-specific survival

DFS
OS
CSS
HR (95%CI)
P value
HR (95%CI)
P value
HR (95%CI)
P value
LVI< 0.001< 0.001< 0.001
No111
Yes3.510 (1.785-6.902)7.373 (2.947-18.45)6.040 (2.314-15.77)
PNI< 0.001< 0.0010.002
No111
Yes3.753 (1.830-7.700)8.259 (2.393-28.50)7.320 (2.090-25.64)
Age (years)0.5060.3930.459
≤ 50111
> 501.494 (0.458-4.873)2.407 (0.321-18.03)2.144 (0.284-16.17)
Sex0.3200.6270.330
Female111
Male1.397 (0.723-2.696)1.251 (0.508-3.081)1.617 (0.615-4.253)
cT stage0.4140.3920.392
2111
31.360 (0.469-3.949)0.5721.231 (0.270-5.627)0.7881.231 (0.270-5.627)0.788
41.539 (0.511-4.634)4.6342.224 (0.663-7.466)0.1962.224 (0.663-7.466)0.196
cN stage0.8690.7330.733
0111
12.446 (0.826-7.238)0.1061.998 (0.423-9.438)0.3821.998 (0.423-9.438)0.382
21.067 (0.553-2.060)0.8471.180 (0.482-2.887)0.7171.180 (0.482-2.887)0.717
Poorly differentiated0.2800.2040.550
No111
Yes1.687 (0.653-4.357)2.228 (0.647-7.678)1.570 (0.358-6.896)
pT stage0.0350.5990.490
2 and 3111
42.580 (1.070-6.220)1.482 (0.342-6.421)1.682 (0.384-7.364)
Mucinous adenocarcinoma0.2090.2240.267
No111
Yes0.468 (0.143-1.529)0.286 (0.038-2.149)0.318 (0.042-2.406)
TD (n)0.1680.3650.470
= 1111
> 11.603 (0.820-3.134)1.540 (0.605-3.919)1.444 (0.533-3.914)
NLN (n)0.0630.1940.116
> 12111
≤ 122.045 (0.961-4.351)1.969 (0.709-5.469)2.308 (0.813-6.554)